Clinical Trials in Washington

Showing 1961-1980 of 8,171 trials

Positive Processes and Transition to Health (PATH)

NCT06093906

The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Health (PATH)'s impact on stressor-related psychopathology in comparison to Progressive Muscle Relaxation (PMR). In the R33 phase, the investigators will examine changes in target mechanisms predicting improvements in PTSD and depressive symptoms, as well as feasibility and acceptability. Patients will receive 6 sessions of PATH or PMR (with 2 boosters, if partial responders). Primary targets will be assessed at pre-treatment, week 3, post-treatment, and at 1- and 3-month follow-up; secondary targets at pre-treatment, weekly during treatment, post-treatment, and at 1- and 3-month follow-ups.

Posttraumatic Stress DisorderMajor Depressive Disorder

Case Western Reserve University135 participantsStarted Sep 2023

Newark, Delaware, United States • Cleveland, Ohio, United States • Seattle, Washington, United States

TERMINATED42 miles

A Long-term Follow-up Study of Patients Who Received VOR33

NCT05309733

VOR33 long-term follow-up (LTFU) study

Leukemia, Myeloid, Acute

Vor Biopharma10 participantsStarted Apr 2022

La Jolla, California, United States • Miami, Florida, United States • Bethesda, Maryland, United States +8 more locations

Positive Processes and Transition to Health (PATH)

A Long-term Follow-up Study of Patients Who Received VOR33

Find Trials by Condition in Washington

mHealth for Psychosis Help-seeking

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Development and Validation of Harbinger Health Test for Early Cancer Detection

Families Moving Forward Bridges: An Early Intervention for Infants and Toddlers With PAE With or At-risk for FASD

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

REhabilitation of MEMory Symptoms After BRain Concussion

Graded Exposure Therapy for Fear Avoidance Behaviour After Concussion

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Enlighten Study: The EV-ICD Post Approval Registry

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)